Phase 1, Open-label, Three Routes IV, Intratumoral Injections and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-ARTEMIS™2™ T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC) is a EARLY_PHASE1 clinical asset sponsored by First Affiliated Hospital Xi'an Jiaotong University in Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Metastatic Liver Cancer. SEO and diligence focus: ET1402L1-ARTEMIS™ T cells -IV, ET1402L1-ARTEMIS™ T cells -intra-hepatic artery, ET1402L1-ARTEMIS™ T cells -Intratumoral Injections, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.